Bionomics to Present Innovations at Global Investment Conference
ADELAIDE, Australia, and CAMBRIDGE, Mass. – Bionomics Limited (NASDAQ: BNOX), an innovative clinical-stage biotechnology company, is thrilled to announce its participation in the H.C. Wainwright 26th Annual Global Investment Conference. This event is scheduled for September 9 to September 11, 2024, and will offer both virtual and in-person attendance options.
CEO Presentation Details
Spyros Papapetropoulos, M.D., Ph.D., the President and CEO of Bionomics, will be presenting at the conference. Attendees can access his presentation on demand starting September 9 at 7:00 AM ET. The focus will be on the company's progress in developing groundbreaking therapies for severe central nervous system (CNS) disorders.
Engagement Opportunities
Alongside the presentation, Bionomics' management team will be available for one-on-one meetings throughout the conference. Investors who wish to connect with the team are encouraged to reach out to their representatives at H.C. Wainwright.
About the Company
Bionomics Limited is leading the charge in creating novel therapeutics that target allosteric ion channels. Their primary candidate, BNC210, is an oral treatment currently being prepared to tackle social anxiety disorder (SAD) and chronic post-traumatic stress disorder (PTSD). Additionally, Bionomics has partnered with Merck & Co., Inc. to advance two early-stage drugs aimed at addressing cognitive impairments linked to Alzheimer's disease and other CNS issues. With a commitment to addressing unmet medical needs, the company's preclinical portfolio includes promising candidates that target specific ion channels essential for CNS health.
Contact Information
If you have any questions, please reach out to:
General Inquiries:
Rajeev Chandra
Company Secretary
Email: CoSec@bionomics.com.au
Investor Relations:
Kevin Gardner
Email: kgardner@lifesciadvisors.com
Investor Relations:
Chris Calabrese
Email: ccalabrese@lifesciadvisors.com
Frequently Asked Questions
What is Bionomics Limited known for?
Bionomics Limited is recognized for its development of innovative allosteric ion channel modulators that target CNS disorders.
When will Bionomics present at the Global Investment Conference?
Dr. Spyros Papapetropoulos will present at the conference, with the presentation available starting September 9, 2024.
How can investors engage with Bionomics during the conference?
Investors can arrange one-on-one meetings with Bionomics' management team through H.C. Wainwright.
What is Bionomics' lead drug candidate?
BNC210 is the leading candidate, aimed at treating social anxiety disorder and PTSD.
Is Bionomics currently involved in any partnerships?
Yes, Bionomics has a strategic partnership with Merck & Co., Inc. to develop two drugs currently in early clinical trials.